Company profile for Kyverna Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body’s own tissues. Kyverna’s therapeutic strategy combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate th...
We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body’s own tissues. Kyverna’s therapeutic strategy combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate these autoreactive immune cells at the root cause of inflammatory disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
740 Heinz Avenue Berkeley, CA 94710
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186763/0/en/Kyverna-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184525/0/en/Kyverna-Therapeutics-to-Present-at-the-Jefferies-London-Healthcare-Conference.html

GLOBENEWSWIRE
10 Nov 2025

https://www.biospace.com/drug-development/kyvernas-car-t-therapy-sets-new-efficacy-standard-in-myasthenia-gravis-de-risking-phase-iii-trials

BIOSPACE
30 Oct 2025

https://www.fiercebiotech.com/biotech/kyverna-links-car-t-improved-autoimmune-outcomes-small-trial

GLOBENEWSWIRE
29 Oct 2025

https://www.globenewswire.com/news-release/2025/10/25/3174164/0/en/Kyverna-Therapeutics-Highlights-Potential-of-KYV-101-in-Rheumatoid-Arthritis-with-Phase-1-Data-from-Investigator-Initiated-Trial-Presented-at-ACR-Convergence-2025.html

GLOBENEWSWIRE
25 Oct 2025

https://www.globenewswire.com/news-release/2025/10/22/3171033/0/en/Kyverna-Therapeutics-to-Host-Conference-Call-on-Interim-Phase-2-Data-from-KYSA-6-Study-of-KYV-101-in-Generalized-Myasthenia-Gravis.html

GLOBENEWSWIRE
22 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty